Selank is a synthetic heptapeptide derived from the endogenous peptide tuftsin, classified as an anxiolytic and nootropic agent. Researchers primarily study Selank for its potential effects on anxiety, cognitive function, and neuroplasticity. Key findings indicate that Selank may enhance brain-derived neurotrophic factor (BDNF) levels in the hippocampus and prefrontal cortex, potentially mitigating memory impairments associated with ethanol exposure, while also exhibiting positive allosteric modulation of GABA receptors. Additionally, studies suggest that Selank may possess antidepressant-like properties, influencing monoaminergic systems and reducing symptoms of depression in animal models. Current research is focused on elucidating the molecular mechanisms underlying its effects and exploring its clinical applications, although comprehensive clinical trials are still needed to establish its efficacy in humans.